CD69 predicts prognosis through immune cell infiltration and decitabine treatment response in acute myeloid leukemia.

ABSTRACT:

Background

Acute myeloid leukemia (AML) is a heterogeneous myeloid neoplasm. Recent studies have focused on unraveling the complexities of the tumor microenvironment (TME) and its impact on AML, with a specific emphasis on CD69, a potential TME regulator. However, the precise relationship between CD69 and AML is yet to be fully elucidated. This study aimed to analyze the heterogeneous gene expression landscape of AML patients using public databases, and to elucidate the relationship between CD69 expression and the pathophysiology of AML.

Methods

Three gene datasets from Gene Expression Omnibus (GEO), ribonucleic acid (RNA) sequence data from The Cancer Genome Atlas (TCGA) and Therapeutically Applicable Research to Generate Effective Treatments (TARGET), and tumor cell lines

SUBMITTER: Zhou J 

PROVIDER: S-EPMC11912086 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature